Thu. 23 May 2024, 5:24pm ET
Benzinga
News
Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics, said "We look forward to sharing the full Phase 1 data set, as well as our biomarker-based patient selection strategy and guidance on the program's next development steps, later this year."